Immunotherapy with a standardized Dermatophagoides pteronyssinus extract *1I. In vivo and in vitro parameters after a short course of treatment

Bousquet, Jean; Calvayrac, P.; Guérin, Bernard; Hejjaoui, A.; Dhivert, H.; Hewitt, B.; Michel, F. B.

doi:10.1016/0091-6749(85)90680-3

Cited by 164 publications

(72 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With respect to molds, one out of two Cladosporium studies documented efficacy (50,51). In DBPC asthma studies assessing efficacy on bronchial challenge (BPT) or exposure tests (63,71) (Table 3), one grass-pollen study noted a reduction in BPT sensitivity (68), as was also the case for one out of three mite studies (65,70,71). Five studies have investigated the efficacy of cat and/or dog immunotherapy (63,64,66,67,69), and three documented a reduction in challenge test or improvement in exposure tests.…”

Section: Clinical Efficacy In Asthmamentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

Section: Clinical Efficacy In Asthmamentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

“…Clinical improvement was accompanied by a decrease in the size of the late-phase cutaneous response after intradermal allergen challenge. It is possible that the efficacy ofimmunotherapy may be related to this ability to inhibit allergen-induced late-phase responses (9)(10)(11)(12). We have previously reported that allergen-induced late-phase cutaneous responses are associated with infiltration by CD4+ T lymphocytes and with the recruitment and activation of eosinophils ( 13).…”

Section: Introductionmentioning

confidence: 99%

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

Varney¹,

Hamid²,

Gaga³

et al. 1993

J. Clin. Invest.

442

264

View full text Add to dashboard Cite

We have studied the influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. In a doubleblind, placebo-controlled trial of immunotherapy in 40 adult hay fever sufferers, clinical improvement was accompanied by a decrease in the size of the late-phase skin response. When the immunotherapy-treated group was compared with the placebo group, analysis of skin biopsies obtained 24 h after intradermal allergen revealed a significant reduction in the number of infiltrating CD3+ (P = 0.04) and CD4+ (P = 0.009) cells and a trend for a decrease in EG2+ eosinophils (P = 0.08). Treatment did not influence allergen-induced recruitment of CD8+ cells, neutrophils, or macrophages. Unexpected increases in expression of CD25 (P = 0.006) and HLA-DR (P = 0.007) were observed in the actively treated group. In situ hybridization using a panel of riboprobes demonstrated "TH2-type" (IL-4, IL-5) cytokine mRNA responses in both groups of patients. In contrast, significant hybridization for IL-2 (8/16 patients, P = 0.02) and for interferon-gamma (6/16 patients, P = 0.04) was observed only in the actively treated group. These findings indicate that immunotherapy is associated with suppression of allergen-induced CD4+ T lymphocyte infiltration, but among the cells that are recruited, there is upregulation of CD25 and HLA-DR. At least in this model, immunotherapy does not appear to affect expression of TH2-pattern cytokines in response to allergen exposure, but expression of mRNA for Thl-type cytokines was enhanced in half of the patients. The results support the view that immunotherapy may possibly be working through induction of T cell tolerance. (J. Clin. Invest. 1993. 92:644-651.)

show abstract

“…The difference in the incidence of systemic reactions between their study and the present study could be caused by the difference in the maintenance dose. They set the maintenance dose in every subject at 3,000 biological units (BU) where injection of 4,000 BU caused systemic reaction in more than half of the subjects (7). We aimed at setting the maintenance dose individually by increasing the dose up to 0.5 ml of 1/10 solution maximally unless a systemic reaction appeared.…”

Section: Discussionmentioning

confidence: 99%

“…Although IT has been generally performed according to the conventional schedule, rush immunotherapy (RI) is an alternative method of IT originally described by Freeman (6) in 1930, reaching a maintenance dose within several days. RI has been confirmed to be effective for the treatment of hypersensitivity to HDM (7), grass pollens (8), hymenoptera (9) or Alternaria (10) using relevant antigen extracts. Wehave previously reported that rush immunotherapy of a 7-day protocol using the HDextract can be carried out safely and securely for HDM-sensitive adult asthmatics (1 1).…”

Section: Introductionmentioning

confidence: 99%

“…Since the maintenance dose can be reached within several days by RI, it is reasonable to expect that the effects of IT on cellular and/or humoral responses against HDMappear much earlier than conventional IT in which it takes a few months, at the earliest, to reach the maintenance dose. Bousquet and associates (7) have reported that RI using Dp extract elicits the clinical efficacy within a few weeks. They also noted the increase in Dp-specific IgG and IgG4 antibodies in sera, the decrease in basophil histamine release and the increase in the threshold dose causing an immediate asthmatic response during an antigen provocation test.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Rush Immunotherapy in House-Dust-Mite (HDM)-Sensitive Adult Bronchial Asthma: Changes in In Vivo and In Vitro Responses to HDM.

et al. 1993

View full text Add to dashboard Cite

Anopen study was conducted to evaluate the changes in in vivo and in vitro responses to housedust-mite (HDM)after rush immunotherapy (RI). A 7-day RI protocol using an extract containing HDM allergen was administered to 12 subjects with HDM-sensitive asthma, and the effects on bronchial responsiveness and serum antibody levels were evaluated up to 16 or 20 weeks after RI. The levels of HDM-specific IgG, IgGl and IgG4 antibodies were significantly elevated from 4 or 8 weeks after RI. Provocative doses causing a 20% fall in FEVX(PD2o) by allergen inhalation were elevated in all subjects at 16 to 20 weeks after RI. There was a high correlation between the increase in log-PD20 and the increase in the ratio ofHDM-specific IgG4 to IgGl (r=0.68,/;<0.05). The results suggest that RI elicits the improvement of allergen-specific bronchial responsiveness and the increase in serum antibody levels within a relatively short period. (Internal Medicine 32: 702-709, 1993)

show abstract

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract *1I. In vivo and in vitro parameters after a short course of treatment

Cited by 164 publications

References 36 publications

Immunotherapy as an effective tool in allergy treatment

Immunotherapy as an effective tool in allergy treatment

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

Effect of Rush Immunotherapy in House-Dust-Mite (HDM)-Sensitive Adult Bronchial Asthma: Changes in In Vivo and In Vitro Responses to HDM.

Contact Info

Product

Resources

About